XBiotech
CompanyUnited States
XBiotech develops one asset, in phase 2 (Natrunix in rheumatoid arthritis). Mostly antibody acting on IL1A and inflammation; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 2
- 2
- Trials
- 1
- Signal
Pipeline
1Neutralizes interleukin-1 alpha to reduce inflammation.
Phase 2, Antibody, IL1A, Inflammation, rheumatoid arthritis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials2
- Signals1
- Similar companies6